Ascendia Pharmaceutical Solutions will exhibit at Booth #779 at the BIO International Convention from June 16–19, 2025, at the Boston Convention & Exhibition Center. The event brings together global leaders in biotechnology and pharmaceutical development for four days of focused partnering and collaboration.
Click here to schedule a meeting with the Ascendia team at BIO 2025.
Ascendia Pharmaceutical Solutions will showcase its CDMO services and capabilities that extend from discovery to commercialization. The award-winning CDMO finds solutions for innovative molecules with solubility, stability, and bioavailability challenges. The company’s expertise includes sterile injectable and oral formulations manufacturing, nanoparticle-based drug delivery, and enabling technologies for poorly water-soluble molecules across all modalities.
Platforms such as NanoSol®, AmorSol®, EmulSol®, and LipidSol® - proprietary to Ascendia Pharmaceutical Solutions – enable targeted solutions for both small molecules and biologics. These technologies are supported by integrated analytical development and a science-driven formulation strategy.
Ascendia Pharmaceutical Solutions offers full development support across the drug lifecycle from discovery, early phase development, to late stage clinical phases, with capabilities that span preclinical formulation screening to cGMP clinical supply. The CDMO, often a Partner of Choice, recently expanded and now operates a 60,000-square-foot facility in the New Jersey Bioscience Center that includes R&D labs, sterile and non-sterile cGMP manufacturing suites, QC and microbial labs, and aseptic fill-finish lines coupled with lyophilization capabilities.
Project teams at Ascendia are structured for flexibility and rapid execution. Clients benefit from real-time access to scientific experts, collaborative program planning, and transparent decision-making throughout the development process.
Ascendia Pharmaceutical Solutions serves our sponsors at various stages of development, advancing complex and high-value therapeutics. The company’s operational model supports aggressive development timelines while maintaining compliance with regulatory standards. It’s all part of the Ascendia Difference, which is how our experienced scientific teams solve complex formulation challenges with our simply elegant technologies.
BIO International Convention provides an opportunity for companies to engage directly with potential CDMO partners. Ascendia Pharmaceutical Solutions’ team will be available at Booth #779 to discuss customized formulation development strategies and manufacturing solutions aligned with sponsor goals.
Ascendia Pharmaceutical Solutions invites the BIO attendees to visit Booth #779 to explore how its capabilities can be tailored to fit their clinical and technical objectives. Biopharma companies seeking a science-driven, flexible CDMO partner for complex formulation challenges are sought and encouraged to schedule a meeting in advance.
Click here to schedule a meeting with the Ascendia team at BIO 2025.